Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Q3 2014 Earnings Presentation
15 slides from Getinge Ab Class B's earnings presentation, Oct 16, 2014
Slide 1: Interim Report January - September 2014
Interim Report January - September 2014 Johan Malmquist, CEO and Ulf Grunander, CFO October 16, 2014 Page 1
Slide 2: Trends in organic order intake
Q3 2014 Trends in organic order intake 2014 2014 Q3 YTD MS EC IC TOT MS EC IC TOT Western Europe -5.7% -3.8 % 3.3 % -3.1% 0.2 % -1.3 % 5.8 % 1.0 % USA and Canada 5.0% -6.7 % -0.6 % 0.3 % 1.9 % -1.3 % 3.6 % 1.2 % Rest of the world 4.4% 0.9 % -1.2 % 2.7 % -6.0 % 9.8 % -2.0 % -3.0 % Total 1.6% -4.1 % 0
Slide 3: Consolidated Results
Q3 2014 Consolidated Results 2014 2013 2014 2013 Q3 Q3 Change % YTD YTD Change % Net sales, SEK million 6 225 5 850 6.4 % 18 184 17 530 3.7 % Gross margin 48.9 % 49.0% -0.1 % 49.0 % 49.9 % -0.9 % Operating cost, SEK -2 303 -2 109 9.2 % -6 894 -6 506 6.0 % million EBITA before 920 907 1.4 % 2 496 2 7
Slide 4: Medical Systems
Q3 2014 Medical Systems 2014 2013 2014 2013 Change % Change % Q3 Q3 YTD YTD Net sales, SEK million 3 258 3 053 6.7 % 9 376 9 010 4.1 % Gross margin % 55.2 % 54.6 % 0.6 % 55.2 % 56.1 % -0.9 % Operating cost, SEK -1 340 -1 268 5.7 % -3 995 -3 858 3.6 % million EBITA before restructuring 589 513 14.8 %
Slide 5: Medical Systems - Highlights
Q3 2014 Medical Systems - Highlights Medical Systems strengthens its quality management systems Remediation cost for quality management system is estimated at approximately SEK 820 M, including a SEK 20 M negative currency translation effect. During the first nine months, SEK 343 M was utilized,
Slide 6: Extended Care
Q3 2014 Extended Care 2014 2013 2014 2013 Change % Change % Q3 Q3 YTD YTD Net sales, SEK million 1 758 1 650 6.5 % 5 162 5 031 2.6 % Gross margin % 46.0 % 47.1 % -1.1 % 46.8 % 47.6 % -0.8 % Operating cost, SEK million -622 -529 17.6 % - 1 878 -1 649 13.9 % EBITA before restructuring 227 280 -18.9 %
Slide 7: Extended Care - Highlights
Q3 2014 Extended Care - Highlights Strengthening of the Flowtron product family for effective Deep Vein Thrombosis (DVT) prevention with applications for: obese patients sequential treatment Q3 REPORT 2014 Page 7
Slide 8: Infection Control
Q3 2014 Infection Control 2014 2013 2014 2013 Change % Change % Q3 Q3 YTD YTD Net sales, SEK million 1 209 1 147 5.4 % 3 646 3 489 4.5 % Gross margin % 36.3 % 36.7 % -0.4 % 36.1 % 37.5 % -1.4 % Operating cost, SEK million -339 -310 9.4 % -1 019 -995 2.4 % EBITA before restructuring 104 114 -8.8 % 30
Slide 9: Infection Control - Highlights
Q3 2014 Infection Control - Highlights The efficiency-enhancement program to improve the business area’s profitability is progressing as planned Acquisition of Austmel Pty Ltd., market leader in Australia of quality assurance systems for sterilization and disinfection The new innovative user-i
Slide 10: Financials Q3
Financials Q3 2014 2013 2014 2013 Q3 Q3 YTD YTD Cash flow from operation, SEK million 742 923 2 081 2 134 Cash conversion, % 60.7 % 78.4 % 78.5 % 65.0 % Net Debt, SEK million 21 360 18 640 Equity, SEK million 16 787 15 314 Equity / assets ratio, % 34.5 % 35.4 % Net debt / equity ratio, multiple 1.27
Slide 11: Outlook
GETINGE GROUP Outlook
Slide 12: Outlook 2014
Outlook 2014 • Demand for capital equipment in developing economies slower than anticipated. Organic invoicing growth is expected to fall somewhat short of previous forecast of 4% • Acquisition and restructuring costs are estimated to amount to approx. SEK 1 billion for 2014, of which SEK 820 M is a
Slide 13: Page 13
GETINGE GROUP
Slide 14: Forward-looking Information
Forward-looking Information This document contains forward-looking information based on the current expectations of the Getinge Group’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expec
Slide 15: Getinge Group is a global leading medical technology company
Getinge Group is a global leading medical technology company that operates in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge Group has more than 15,000 employees in over 40 countries and generates sales exceeding SEK 25 billion (2013). The Group is d